Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with or without rhenium-188 HEDP in castration-resistant prostate cancer with bone metastases
NL-OMON39120Phase 2Active, not recruiting
- Sponsor
- Meander Medical Center
- Start
- Aug 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Docetaxel monotherapy with Docetaxel + rhenium-188 HEDP (2 arms). Primary endpoint: Time to progression. Started Aug 2012; status: active, not recruiting.
02
Drugs
docetaxelRhenium-188-HEDP
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON39120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39120.